← Our News

Research & clinical trials, Information & guidance, Campaigns & awareness, For health professionals

Have your say in shaping future priorities of neuroendocrine cancer research

By Beth Chesser

Posted 6 months ago

26/05/2026 10am
Getting your Trinity Audio player ready...

Update: Second National Survey to Identify Research Priorities in Neuroendocrine Cancer 

The JLA Neuroendocrine Cancer Priority Setting Partnership continues to make strong progress, with the project moving into its next key phase. 

CLICK HERE TO TAKE PART

Following the successful completion and analysis of the initial survey, preparations are now underway for the second survey, which is due to open on 18 May to 22 June. This survey will ask patients, carers, and healthcare professionals to review and prioritise the research questions identified so far, helping to refine the list of uncertainties that matter most to the neuroendocrine cancer community. The survey is quick to complete and responses are completely confidential. Findings from this stage will inform a final prioritisation process, bringing together patients, carers, and clinicians to agree on a top 10 list of research priorities. 

 

The second survey is open to: 

  • People living with neuroendocrine cancer  
  • Family members, carers, and supporters  
  • Healthcare professionals involved in diagnosis, treatment, or care  

 

By taking part, individuals can directly influence the direction of research and help ensure that it reflects real-world needs and experiences. This is a crucial step in making research more patient-centred and impactful. 

Looking ahead, the final priority setting workshop is planned for early July. This workshop will bring together patients, carers, and clinicians to agree on the top research priorities that will guide future funding and research efforts in neuroendocrine cancer. 

CLICK HERE TO TAKE PART

Engagement remains central to the process, and efforts are ongoing to ensure broad participation across all stakeholder groups to capture a diverse range of perspectives. 

Further updates will be shared as the partnership approaches these important milestones. 

 

Catch up on the latest news, stories and updates

Ongoing variability in the supply of pancreatic enzyme replacement therapy (PERT) — particularly Creon® 25,000iu capsules — has left some people struggling to obtain their prescription. ...